Your browser is no longer supported. Please, upgrade your browser.
KTOV Kitov Pharma Ltd daily Stock Chart
Kitov Pharma Ltd
Index- P/E- EPS (ttm)-7.80 Insider Own4.67% Shs Outstand17.21M Perf Week2.14%
Market Cap73.83M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.97M Perf Month-10.63%
Income- PEG- EPS next Q- Inst Own28.19% Short Float12.94% Perf Quarter-24.60%
Sales1.00M P/S73.83 EPS this Y- Inst Trans- Short Ratio0.23 Perf Half Y71.67%
Book/sh9.28 P/B0.46 EPS next Y- ROA- Target Price- Perf Year-47.04%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.20 - 14.40 Perf YTD-44.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.81% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low91.05% ATR0.39
Employees9 Current Ratio- Sales Q/Q0.00% Oper. Margin- RSI (14)37.10 Volatility5.38% 7.75%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.11 Prev Close4.29
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.79M Price4.20
Recom- SMA20-1.25% SMA50-32.03% SMA200-29.28% Volume101,531 Change-2.03%
Nov-21-17Upgrade H.C. Wainwright Neutral → Buy $10
Feb-16-16Initiated Rodman & Renshaw Buy $10
Sep-08-20 07:10AM  
Sep-04-20 08:00AM  
Aug-12-20 04:55PM  
Aug-11-20 07:15AM  
Jul-09-20 07:30AM  
Jul-08-20 07:30AM  
Jul-02-20 08:34AM  
Jun-25-20 04:30PM  
Jun-23-20 01:20PM  
May-22-20 07:00AM  
May-20-20 07:30AM  
May-19-20 08:05AM  
May-14-20 07:10AM  
May-08-20 04:00PM  
May-06-20 08:00AM  
Apr-20-20 08:05AM  
Mar-17-20 08:00AM  
Mar-12-20 08:15AM  
Feb-24-20 09:00AM  
Feb-11-20 07:00AM  
Feb-03-20 08:20AM  
Jan-24-20 08:10AM  
Jan-09-20 08:35AM  
Jan-08-20 07:30AM  
Oct-11-19 08:54AM  
Oct-02-19 08:20AM  
Sep-09-19 08:30AM  
Sep-03-19 08:22AM  
Aug-29-19 08:30AM  
Aug-16-19 08:24AM  
Aug-14-19 08:20AM  
Aug-08-19 08:20AM  
Jul-12-19 05:11PM  
Jun-27-19 07:30AM  
May-10-19 09:20AM  
May-09-19 08:30AM  
May-02-19 04:45PM  
Apr-12-19 08:28AM  
Mar-18-19 08:20AM  
Mar-14-19 02:30PM  
Feb-07-19 08:06AM  
Jan-21-19 08:30AM  
Jan-18-19 04:30PM  
Jan-16-19 04:26PM  
Jan-15-19 02:01PM  
Jan-07-19 12:25PM  
Jan-03-19 08:35AM  
Oct-15-18 08:00AM  
Oct-11-18 08:26AM  
Sep-26-18 09:40AM  
Sep-18-18 12:57PM  
Aug-29-18 08:00AM  
Jul-30-18 07:47AM  
Jul-17-18 07:35AM  
Jun-27-18 09:17AM  
Jun-15-18 09:31AM  
Jun-01-18 08:40AM  
May-31-18 01:45PM  
May-15-18 07:00AM  
May-11-18 08:30AM  
Apr-13-18 09:21AM  
Mar-13-18 08:25AM  
Mar-08-18 09:33AM  
Mar-05-18 09:35AM  
Dec-14-17 09:40AM  
Nov-01-17 09:15AM  
Oct-26-17 02:00PM  
Oct-06-17 08:20AM  
Oct-04-17 07:50AM  
Oct-02-17 07:00AM  
Aug-16-17 04:35PM  
Jul-31-17 03:20PM  
Jul-18-17 08:36AM  
Jul-11-17 09:28AM  
Jul-07-17 07:25AM  
Jun-26-17 02:37PM  
Jun-15-17 10:55AM  
May-01-17 10:19AM  
Apr-06-17 02:49PM  
Apr-05-17 01:16PM  
Apr-04-17 03:46PM  
Apr-03-17 09:58AM  
Apr-02-17 01:36PM  
Mar-31-17 07:12PM  
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd is headquartered in Tel Aviv, Israel.